ABBVAbbVieNot started yet
A Study to Evaluate Adverse Events and Change in Disease Activity With Injected Etentamig Plus Oral Pomalidomide Versus Standard Therapies in Adults With Relapsed or Refractory Multiple Myeloma
Relapsed or Refractory Multiple Myeloma
0Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 3
- Patients
- 520 (planned)
- Started
- Nov 30, 2026
- Main results expected
- Feb 2033
- Fully finished
- Feb 2033
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Safety Run-In: Number of Participants With Adverse Events (AE)s
Measured over: Up to Approximately 75 Months
Randomized Portion: Complete Response (CR) or Better Rate Per Independent Review Committee (IRC) Assessment
Measured over: Up to Approximately 75 Months
Randomized Portion: Progression-Free Survival (PFS) Per Independent Review Committee (IRC) Assessment
Measured over: Up to Approximately 75 Months
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT07728188 · record last updated 2026-07-27 · checked 2026-11-09 15:47 UTC